Company profile
MannKind Corporation
NASDAQ: MNKD · Healthcare · Biotechnology
PublicHQ Danbury, CACIK 0000899460Reports USD
#236 of 1,422 Healthcare companies by revenue68th-percentile growth
EA Score
69BFH 58DQ 81GM 72SS 81
v0.1 · 65/100 weight · provisional
↑ disclosure history, operating margin · ↓ Piotroski F, balance-sheet leverage
Methodology →Revenue TTM
$360.8M
Rev growth YoY (TTM)
+21.2%
Net income (FY)
$5.9M
Employees
592
as of 2026-08-09
Market cap
$1.3B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$349.0M$349.0M2025
Net income$5.9M$5.9M2025
Operating income$38.8M$38.8M2025
Total assets$792.2M$792.2M2025
Liabilities$843.2M$843.2M2025
Equity-$51.0M-$51.0M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product Revenue62%
Royalty37%
Service1%
By geography
Not disclosed.
The read
What is MannKind Corporation’s revenue?
MannKind Corporation booked $349.0M in FY2025 revenue, growing 22% year over year — faster than most Healthcare companies we track, at a 1.7% net margin.
Peers · Healthcare
Twist Bioscience Corporation70BArcutis Biotherapeutics, Inc.66BAtea Pharmaceuticals, Inc.47DTruBridge, Inc.75B+Castle Biosciences, Inc.70BTactile Systems Technology, Inc.83B+Key facts
CEOMichael E. Castagna
SectorHealthcare
IndustryBiotechnology
HeadquartersDanbury, CA
ExchangeNASDAQ: MNKD
Employees592
IPO date2004-07-28
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.